BioSpace News Archive

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results as of and for the quarter ended September 30, 2020. Third Quarter Highlights Assay revenues of $1.2 million for the third quarter of 2020, a 220% increase compared to the third quarter of 2019 and a 90% sequential increase over the secon

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Stifel 2020 Virtual Healthcare Conference. Webcast Information Forte management will host a webcast

- U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 - - Conference call and webcast to be hosted today at 4:30pm EDT -

GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) - - GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer Meeting 2020 -

Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program highlights for the third quarter ended September 30, 2020. “Several months into UPLIZNA’s launch, we have gained valuable insights into how to meet our customer’s needs, which continue to evolve during the COVI

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the quarter ended September 30, 2020 and prov

Jaguar Health, Inc. today announced that Company management will host a conference call on Monday, November 16, 2020 at 8:30 a.m. Eastern Time to review third-quarter 2020 financials and provide business updates.

All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance Median progression-free survival (PFS) improved from 7.4 months to 9.5 months. Hazard ratio (HR) 0.68 (95% CI: 0.44-1.04) p=0.073 Median overall survival (OS) improved from 12.9 months to not reached. HR 0.58 (95% CI: 0.35-0.95) p=0.027 Overall response rate (ORR) improved by 13.1% (p=0.106)

Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for life sciences and high tech companies, today announced financial results for the fourth quarter and fiscal year 2020 ended September 30, 2020. “As we announced in October, our fourth quarter results exceeded our guidance across all key metrics which resulted in another quarter of profitable growth and a strong finish to the

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 9:20 a.m. EST. A live audio webcast of the presentation can be accessed through the Events section of th